Benign prostatic hyperplasia (BPH) is the benign enlargement, or hypertrophy, of the prostate gland resulting from an increase in the number of epithelial cells and stromal tissue, developing upward into the bladder and obstructing the outflow of urine.

• It is defined as a noncancerous increase in the size of the prostate gland which involves hyperplasia of prostatic stromal and epithelial cells. This results in the formation of large, fairly discrete nodules in the transitional zone of the prostate, which push on and narrow the urethra, resulting in increased resistance to the flow of urine from the bladder.
• It is the most common urologic problem in male adults.

• BPH is common in elderly men over 60 years and above.
• In many patients older than 50 years, the prostate gland enlarges, extending upward into the bladder and obstructing the outflow of urine by encroaching on the vesicle orifice.
• About 50% of all men in their lifetime will develop BPH. Of these men, almost half of them will have bothersome lower urinary tract symptoms.
• 50% of men have evidence of BPH by age 50 years.
• 75% of men have evidence of BPH by age 80 years.

The exact cause of BPH is idiopathic, but several factors are strongly associated with its development:

• Aging: Prostate gland enlargement rarely causes signs and symptoms in men younger than age 40. About one-third of men experience moderate to severe symptoms by age 60, and about half do so by age 80. Aging occurs along with endocrine factors.
• Hormonal Factors (Endocrine): Accumulation of Dihydrotestosterone (DHT) in the prostate.
• Family History: Having a blood relative, such as a father or brother, with prostate problems means a higher likelihood of having problems.
• Ethnic Background: Prostate enlargement is less common in Asian men than in White and Black men.
• Diabetes and Heart Disease: Studies show that diabetes, as well as heart disease and the use of beta-blockers, might increase the risk of BPH.
• Lifestyle and Obesity: Obesity increases the risk of BPH, while exercise can lower the risk.
• Inflammation: Chronic prostatic inflammation.
• Moderate Alcohol Consumption: Sometimes implicated, though heavy consumption has complex systemic effects.

The outcome of BPH depends on two major factors:

• Anatomical factors: These involve the physical enlargement of the Prostate gland which produces a physical blockage at the neck of the bladder against urinary flow. This results from increased responsiveness of the prostate gland to androgens and estrogens.
• Dynamic factors: These result from excessive sympathetic stimulation via alpha-1 receptors in the prostate gland leading to increased tone at the sphincters of the urinary bladder and the prostate.

1. Due to etiological factors like aging, there is a decrease in systemic testosterone levels.
2. However, testosterone is actively converted into Dihydrotestosterone (DHT) by the enzyme 5-alpha reductase.
3. DHT accumulates in the stromal cells of the prostate.
4. This leads to the enlargement of the prostate (noncancerous increase involving hyperplasia of stromal and epithelial cells).
5. Large discrete nodules form in the transitional zone, which push on and narrow the urethra.
6. This results in increased resistance to flow and eventual obstruction of urine flow from the bladder.

• Resistance: BPH is a result of complex interactions involving resistance in the prostatic urethra to mechanical and spastic effects.
• Obstruction: The hypertrophied lobes of the prostate obstruct the bladder neck or urethra, causing incomplete emptying of the bladder and urinary retention.
• Dilation: Gradual dilation of the ureters (hydroureter) and kidneys (hydronephrosis) can occur due to backpressure.

The clinical manifestations are broadly divided into obstructive and irritative symptoms (a complex referred to as prostatism), along with generalized systemic symptoms and complications.

• Hesitancy: Difficulty in starting urination.
• Decrease in volume and force: A weak urinary stream. Decreased and intermittent force of the stream is a classic sign.
• Interruption of urinary stream: Intermittency during urination (stopping and starting).
• Dribbling: Urine dribbles out at the end of urination.
• Abdominal straining: Using abdominal muscles to force urine out.

• Urinary frequency: Frequent trips to the bathroom. Often an early sign.
• Urinary urgency: The sudden and immediate urge to urinate.
• Nocturia: Waking up frequently at night to urinate.
• Sensation of incomplete emptying: Feeling that the bladder has not been completely emptied after voiding.

• Acute urinary retention: Sudden inability to void, leaving more than 60 mL of urine in the bladder after an attempt.
• Recurrent Urinary Tract Infections (UTIs): Due to stagnant urine.
• Hematuria: Blood in the urine.
• Systemic symptoms: Fatigue, anorexia, nausea, vomiting, pelvic discomfort, pain, and epigastric symptoms.
• Azotemia and Renal Failure: Can result from chronic urinary retention and large residual volumes.

If left untreated, severe obstruction can lead to:

• Acute urinary retention
• Involuntary bladder contractions
• Bladder diverticula (pouch-like out-pouchings of the bladder wall)
• Cystolithiasis (bladder stones)
• Vesicoureteral reflux (urine backing up into ureters)
• Hydroureter and Hydronephrosis (swelling of ureters and kidneys)
• Gross hematuria
• Recurrent UTIs
• Renal failure

The goals of collaborative care and medical management are to:

1. Restore bladder drainage.
2. Relieve patient symptoms and improve quality of life.
3. Prevent and treat complications of BPH.

The treatment plan depends on the cause, severity of obstruction, and condition of the patient.

• Immediate Catheterization: If a patient is admitted on an emergency basis because he is unable to void (acute retention), he is immediately catheterized. An urologist may be consulted if an ordinary catheter cannot be inserted (may require a Coudé tip catheter).
• Suprapubic Cystostomy: An incision into the bladder through the abdomen may be needed to provide urinary drainage if urethral catheterization fails.
• "Watchful Waiting" (Active Surveillance): For patients with minimal symptoms. Involves monitoring disease progression and modifying diet and lifestyle.

Drug therapy primarily involves three major groups: 5-alpha reductase inhibitors, Alpha-1 selective blockers, and Combination therapy. PDE5 inhibitors and herbal supplements are also utilized.

• Increase intake of fruits and vegetables.
• Decrease foods high in saturated fat.
• Avoid excessive intake of caffeine, alcohol, and beer (these have diuretic effects and can irritate the bladder).
• Drink 50% of your body weight in ounces daily (e.g., if you weigh 150 lbs, drink 75 oz of water daily), but avoid drinking large amounts at once or close to bedtime.
• Include Saw Palmetto in the diet (as per some holistic guidelines, though clinically debated).

Minimally invasive therapies are becoming more common as an alternative to watchful waiting and invasive surgical treatment. They generally do not require hospitalization or long-term catheterization and are often performed as outpatient procedures.

1. Transurethral Microwave Thermotherapy (TUMT):
   • Procedure: An outpatient procedure involving the delivery of microwaves directly to the prostate through a transurethral probe to raise the temperature to about 113°F (45°C). The heat causes the death (necrosis) of tissue, relieving obstruction.
   • Details: Takes about 90 minutes. A rectal temperature probe is utilized to ensure the temperature is kept below 110°F (43.5°C) to prevent rectal tissue damage.
   • Contraindications: Not appropriate for men with rectal problems. Anticoagulant therapy must be stopped 10 days before treatment.
   • Complications & Care: Postoperative urinary retention is common. Patients are sent home with an indwelling catheter for 2 to 7 days to facilitate the passing of small clots and necrotic tissue. Treated with antibiotics, pain medications, and bladder antispasmodics. Occasional bladder spasms, hematuria, and dysuria.
2. Transurethral Needle Ablation (TUNA):
   • Procedure: Uses low-wave radiofrequency delivered by thin needles placed directly into the prostate gland to produce localized heat/necrosis. Only tissue in direct contact with the needle is affected, allowing high precision.
   • Details: Extent of removal depends on needle length, energy, and duration. Outpatient, local anesthesia with IV/oral sedation, lasts ~30 minutes. Little pain with an early return to normal activities.
   • Complications: Urinary retention (may require a catheter for a short time), UTI, irritative voiding symptoms, and hematuria for up to a week.
3. Laser Prostatectomy:
   • Procedure: A laser beam is delivered transurethrally through a fiber instrument to cut, coagulate, and vaporize prostatic tissue under visual or ultrasound guidance. Effective alternative to TURP.
   • Types: Visual Laser Ablation of Prostate (VLAP), Contact laser technique.
4. Photovaporization of the Prostate (PVP):
   • Uses a high-power green laser light to vaporize tissue. Improvements in urine flow are almost immediate. Bleeding is minimal. A catheter is usually inserted for 24-48 hours. Works well for larger glands.
5. Interstitial Laser Coagulation (ILC):
   • Prostate is viewed through a cystoscope. A laser quickly treats precise areas via the direct placement of interstitial light guides into the tissue.
6. Intraprostatic Urethral Stents:
   • Used for patients with severe obstruction who are poor surgical candidates. A stent is placed in the urethra to mechanically relieve symptoms.
   • Complications: Chronic pain, infection, and encrustation (stone formation on the stent).

Invasive treatment of symptomatic BPH involves surgery. The choice depends on the size/location of enlargement and patient factors (age, surgical risk).

• Intermittent Catheterization: Can temporarily reduce symptoms by bypassing the obstruction, but long-term use should be avoided due to the high risk of infection.
• Transurethral Resection of the Prostate (TURP):
  • Description: Considered the gold standard for surgical treatment of obstructing BPH. Involves the removal of inner prostate tissue using a resectoscope inserted through the urethra to excise and cauterize the tissue. No external incision is made.
  • Procedure Details: Done under spinal or general anesthesia; requires a 1 to 2-day hospital stay.
  • Post-Operative Irrigation: A large three-way indwelling catheter with a 30-mL balloon is inserted to provide hemostasis (by putting traction on the balloon against the prostatic fossa) and facilitate drainage. The bladder undergoes Continuous Bladder Irrigation (CBI) or intermittent irrigation for the first 24 hours to prevent obstruction from mucus and blood clots.
  • Outcomes & Complications: 80-90% excellent outcome. Complications include bleeding, clot retention, and TURP Syndrome (dilutional hyponatremia caused by the systemic absorption of the irrigation fluid, leading to confusion, nausea, and changes in BP). Urethral strictures or regrowth of the prostate may occur.
• Transurethral Incision of the Prostate (TUIP):
  • Done under local anesthesia. Indicated for patients with moderate to severe symptoms but small to moderately enlarged prostates. Several small incisions are made into the gland to expand the urethra. Relieves pressure without removing tissue. Similar outcomes to TURP for appropriate candidates.
• Transurethral Electrovaporization of Prostate (TUVP):
  • Uses electrosurgical desiccation to destroy tissue. Advantages include minimal risk, minimal bleeding, and sloughing. Complications include retrograde ejaculation and hematuria.
• Open Prostatectomy:
  • Indicated only when the prostate is very large or if there are complicating factors (e.g., large bladder stones).
  • Approaches: Retropubic, Suprapubic, or Perineal approach.
  • Side effects/Complications: Higher risk of erectile dysfunction, heavy bleeding, severe post-operative pain, and a higher risk of infection.

• Early Detection: Encourage annual DRE and PSA testing for men over 50.
• Substance Avoidance: Advise reducing the intake of caffeine and alcohol to decrease bladder irritation.
• Medication Warnings: Strongly advise patients to avoid OTC cold and cough medications containing sympathomimetics (like pseudoephedrine/phenylpropanolamine) or anticholinergics, as these can severely impair voiding and precipitate acute urinary retention.
• Symptom Reporting: Explain to patients not undergoing treatment the symptoms of complications (retention, cystitis) and encourage prompt reporting.
• Expectation Management: Advise patients that irritative voiding symptoms do not immediately resolve after the relief of the obstruction; the bladder needs time to heal and adapt.

• Urinary drainage must be restored before surgery (e.g., via catheterization) if the patient is in retention.
• Antibiotics are administered to prevent intraoperative infection.
• Psychological Care: Allow the patient to express sexual concerns (fears regarding erectile dysfunction or retrograde ejaculation post-surgery).

• Catheter and Irrigation Management (CBI): Ensure the inflow and outflow of irrigant are strictly monitored to prevent fluid volume overload and bladder rupture. The rate of irrigation is adjusted to keep the output urine light pink to clear.
• Clot Prevention: Remove clotted blood from the bladder via manual irrigation if the 3-way catheter becomes obstructed.
• Bleeding Control: Reduce bleeding at the prostate site by applying counterpressure (traction on the catheter balloon).
• Bladder Spasms: Prevent and treat painful bladder spasms with prescribed antispasmodics (e.g., B&O suppositories, Oxybutynin).
• Infection Control: Prevent urethral irritation and bladder infection through strict aseptic catheter care.
• Activity: Straining during bowel movements must be strictly avoided. Provide stool softeners/laxatives. Have the patient practice pelvic floor (Kegel) exercises once the catheter is removed to regain continence.

• Care of the urinary catheter (if discharged with one).
• Managing temporary urinary incontinence (using pads, Kegel exercises).
• Intake of oral fluids: 2000-3000 mL/day to maintain clear urine and flush out dead tissue/clots.
• Observing for signs of urinary tract and wound infection.
• Preventing constipation (dietary fiber, stool softeners).
• Restrictions: Refrain from heavy lifting, driving, long periods of sitting, and sexual intercourse for 6 to 8 weeks after surgery, until the prostatic fossa is completely healed.
• Follow-up: Advise strict follow-up visits because urethral strictures may occur, and regrowth of the prostate is possible after TURP.

Thus, BPH is a disease affecting older adults which leads to minor symptoms like urinary frequency to major complications like complete urinary retention and renal failure. Early detection, lifestyle modification, targeted pharmacological treatment, and appropriate surgical management show a very good prognosis.

• Brunner, L. S., & Suddarth, D. S. (2021). Brunner & Suddarth's Textbook of Medical-Surgical Nursing (15th ed.). Wolters Kluwer.
• Lewis, S. L., Dirksen, S. R., Heitkemper, M. M., & Bucher, L. (2017). Medical-Surgical Nursing: Assessment and Management of Clinical Problems (10th ed.). Elsevier.
• Katzung, B. G., & Trevor, A. J. (2021). Basic & Clinical Pharmacology (15th ed.). McGraw-Hill Education.
• American Urological Association (AUA) Guidelines on the Management of Benign Prostatic Hyperplasia.
• Doenges, M. E., Moorhouse, M. F., & Murr, A. C. (2019). Nursing Care Plans: Guidelines for Individualizing Client Care Across the Life Span (10th ed.). F.A. Davis Company.